Pivanex
CAS No. 122110-53-6
Pivanex ( AN-9; Pivalyloxymethyl butyrate )
产品货号. M26790 CAS No. 122110-53-6
Pivanex is an orally active HDAC inhibitor and an antimetastatic and antiangiogenic agent. Pivanex downregulates the Bcr-Abl protein and enhances apoptosis.
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
规格 | 价格/人民币 | 库存 | 数量 |
5MG | ¥316 | 有现货 |
|
10MG | ¥478 | 有现货 |
|
25MG | ¥988 | 有现货 |
|
50MG | ¥1531 | 有现货 |
|
100MG | ¥2333 | 有现货 |
|
200MG | ¥3467 | 有现货 |
|
500MG | ¥5557 | 有现货 |
|
1G | 获取报价 | 有现货 |
|
生物学信息
-
产品名称Pivanex
-
注意事项本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
-
产品简述Pivanex is an orally active HDAC inhibitor and an antimetastatic and antiangiogenic agent. Pivanex downregulates the Bcr-Abl protein and enhances apoptosis.
-
产品描述Pivanex is an orally active HDAC inhibitor and an antimetastatic and antiangiogenic agent. Pivanex downregulates the Bcr-Abl protein and enhances apoptosis.(In Vitro):In K562 cells, Pivanex (100-500 μM) exhibits significant anti-proliferation activity and enhances apoptosis and caspase activity. Pivanex (200 μM) induces enhancement in the G2-M phase, a moderate enhancement in the S phase, and a slight reduction in G0-G1 of the cell cycle.(In Vivo):Pivanex(200 mg/kg, b.i.d, daily) treatment marked delays in the end stage of disease as defined by the onset of body mass loss by 94.9%. Pivanex(200 mg/kg, b.i.d, daily) obviously improves the survival of SMN7 SMA mice by 84.6%.
-
同义词AN-9; Pivalyloxymethyl butyrate
-
通路Apoptosis
-
靶点Apoptosis
-
受体GSK-3α; GSK-3β
-
研究领域——
-
适应症——
化学信息
-
CAS Number122110-53-6
-
分子量202.3
-
分子式C10H18O4
-
纯度>98% (HPLC)
-
溶解度——
-
SMILESCCCC(=O)OCOC(=O)C(C)(C)C
-
化学全称——
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1.Prabhakaran J, et al. Radiosynthesis and in Vivo Evaluation of [11C]A1070722, a High Affinity GSK-3 PET Tracer in Primate Brain. ACS Chem Neurosci. 2017 Aug 16;8(8):1697-1703.
产品手册
关联产品
-
NecroX-7
NecroX-7 is a small molecule necrosis modulator and potent antioxidant molecule.
-
Cl-amidine hydrochlo...
Cl-amidine hydrochloride is an orally active peptidylarginine deminase (PAD) inhibitor (IC50: 5.9 μM for PAD4).
-
Silvestrol
Silvestrol is a potential anticancer rocaglate derivative from Aglaia foveolata, induces apoptosis in cancer cells through the mitochondrial/apoptosome pathway.